Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dithranol allergy: fact or fiction?

A D Burden1, M Stapleton, M H Beck

  • 1Skin Hospital, Salford, UK.

Contact Dermatitis
|November 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Informed consent in gynecological oncology: a JAGO/NOGGO survey on real-world practices in daily clinical routine.

Archives of gynecology and obstetrics·2024
Same author

Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.

Experimental dermatology·2023
Same author

Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).

The British journal of dermatology·2021
Same author

Psoriasis, COVID-19 and shielding.

The British journal of dermatology·2021
Same author

Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

This case study highlights a psoriatic patient with allergies to both dithranol and coal tar. A low concentration of dithranol (0.001% pet.) is proposed for allergy testing to avoid irritant reactions.

Area of Science:

  • Dermatology
  • Allergology
  • Pharmacology

Background:

  • Psoriasis treatment often involves topical agents like dithranol and coal tar.
  • Allergic reactions to these treatments can complicate patient management.
  • Understanding cross-reactivity is crucial for effective therapeutic strategies.

Observation:

  • A specific case of a psoriatic patient experiencing allergic reactions to both dithranol and coal tar is presented.
  • The patient's sensitivity necessitated a review of potential diagnostic approaches.

Findings:

  • A low concentration of dithranol (0.001% in petrolatum) is suggested as a safe and effective concentration for patch testing to identify dithranol allergy.
  • Higher concentrations of dithranol may elicit irritant responses rather than true allergic reactions, confounding diagnosis.

Related Experiment Videos

  • The literature review indicates a frequent co-occurrence of simultaneous reactions to dithranol and coal tar in sensitive individuals.

    • Implications:

    • This finding aids in the accurate diagnosis of dithranol allergy in psoriatic patients.
    • It provides guidance on selecting appropriate concentrations for diagnostic patch testing.
    • Understanding the link between dithranol and coal tar allergies can inform safer treatment choices for psoriasis.